Journal of Medical Economics

Article	Citations
Health outcomes and economic burden of hospitalized COVID-19 patients in the United States	137
The Global South political economy of health financing and spending landscape – history and presence	80
Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis	46
Iran, sanctions, and the COVID-19 crisis	40
Asian innovation in pharmaceutical and medical device industry – beyond tomorrow	40
Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2	39
How China controls the Covid-19 epidemic through public health expenditure and policy?	38
Chronic wound prevalence and the associated cost of treatment in Medicare beneficiaries: changes between 2014 and 2019	30
Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer	28
Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison	27
Setting and maintaining standards for patient-reported outcome measures: can we rely on the COSMIN checklists?	26
Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United Sta	25
The societal economic value of COVID-19 vaccines in the United States	23
Economic implications of the modern treatment paradigm of glioblastoma: an analysis of global cost estimates and their utility for cost assessment	23
Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China	22
Mean lifetime survival estimates following solid organ transplantation in the US and UK	21
Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endom	21
A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome	19
Economic modeling of reSET-O, a prescription digital therapeutic for patients with opioid use disorder	18
Economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the United States: a societal perspective	17
Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegf	17
Consequences of India’s population aging to its healthcare financing and provision	17
Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States	16
Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States	16
Technical and regulatory challenges of digital health implementation in developing countries	16

Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States	16
Corneal cross-linking versus conventional management for keratoconus: a lifetime economic model	15
Applications of AI in pharmacy practice: a look at hospital and community settings	15
Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries	15
Carbon footprint and associated costs of asthma exacerbation care among UK adults	14
Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States	14
Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers	14
Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States	14
Burden of caring for Alzheimer’s disease or dementia patients in Japan, the US, and EU: results from the National Health and Wellness Survey: a cross-sectional survey	13
Cost-effectiveness of a novel hybrid closed-loop system compared with continuous subcutaneous insulin infusion in people with type 1 diabetes in the UK	13
Therapeutic innovations: the future of health economics and outcomes research – increasing role of the Asia-Pacific	13
Humanistic burden among caregivers of patients with Alzheimer’s disease or dementia in Japan: a large-scale cross-sectional survey	13
Cost-effectiveness of the cell-based quadrivalent versus the standard egg-based quadrivalent influenza vaccine in Germany	13
Productivity loss and productivity loss costs to United States employers due to priority conditions: a systematic review	12
Cost-effectiveness analysis of carbetocin versus oxytocin for the prevention of postpartum hemorrhage following vaginal birth in the United Kingdom	12
Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Denmark compared with PPV23	12
Chronic kidney disease in Spain: analysis of patient characteristics, incidence and direct medical costs (2011–2017)	12
The direct and indirect economic burden of hypothyroidism in the United States: a retrospective claims database study	12
Health and economic burden of invasive pneumococcal disease associated with 15-valent pneumococcal conjugate vaccine serotypes in children across eight European countries	11
Impact of an active hemostatic product treatment approach on bleeding-related complications and hospital costs among inpatient surgeries in the United States	11
Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer	11
The impact of seven major noncommunicable diseases on direct medical costs, absenteeism, and presenteeism in Gulf Cooperation Council countries	11
Cost savings with hemin versus givosiran for the treatment of patients with acute intermittent porphyria (AIP)	11
Hospitalization costs of adult community-acquired pneumonia in England	11
Cost-effectiveness of letermovir as cytomegalovirus prophylaxis in adult recipients of allogeneic hematopoietic stem cell transplantation in Hong Kong	11
Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer	11
Economic burden for retinoblastoma patients in China	11
National and regional description of healthcare measures among adult Medicaid beneficiaries with schizophrenia within the United States	11
Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK	11
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations	11
Healthcare resource use and indirect costs associated with migraine in Italy: results from theMy Migraine Voicesurvey	11
Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemoth	10
An analysis of the cost-effectiveness of transcatheter mitral valve repair for people with secondary mitral valve regurgitation in the UK	10
Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany	10
Economic burden of respiratory syncytial virus infection in adults: a systematic literature review	10
Modeling the economic value of Ceribell Rapid Response EEG in the inpatient hospital setting	10
The PRIME Type 2 Diabetes Model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus	10
Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan	10
COVID-19-associated hospitalizations among children less than 12 years of age in the United States	10
Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population	10
Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model	10
Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China	10
Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease	10
Breast cancer-related mortality in Central and Eastern Europe: years of life lost and productivity costs	10
Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain	9
Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a MET exon 14 skipping mutation in the United States	9
Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial	9
Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore’s private insurance payer’s perspective	9
Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in children in the United States	9
Modelling the value of innovative treatments for Alzheimer’s disease in the United States	9

Cost-effectiveness of influenza vaccination with a high dose quadrivalent vaccine of the elderly population in Belgium, Finland, and Portugal	9
Hospital incidence, management and direct cost of osteogenesis imperfecta in Spain: a retrospective database analysis	9
The potential clinical impact of implementing different COVID-19 boosters in fall 2022 in the United States	9
Epidemiology and economic burden of Huntington’s disease: a Canadian provincial public health system perspective	9
Burden of illness among Medicare and non-Medicare US populations with acquired thrombotic thrombocytopenic purpura	9
Economic evaluation of a JAK inhibitor compared to a monoclonal antibody for treatment of moderate-to-severe atopic dermatitis from a UK perspective	9
The impact of transparency constraints on the efficiency of the Russian healthcare system: systematic literature review	9
Utilities associated with stoma-related complications: peristomal skin complications and leakages	9
Clinical and economic burden of HPV-related cancers in the US veteran population	9
Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States	8
Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment	8
Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain	8
Informing a cost-effectiveness threshold for Saudi Arabia	8
Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany	8
Impact of choice of inhalers for asthma care on global carbon footprint and societal costs: a long-term economic evaluation	8
Identification of undiagnosed atrial fibrillation using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI) in primary care: cost-effectiveness of a screening strategy evalu	8
Quality outcomes, healthcare resource utilization and costs in Medicare patients with chronic heart failure with reduced ejection fraction with and without a worsening event	8
Estimation of the value of convenience in taking influenza antivirals in Japanese adult patients between baloxavir marboxil and neuraminidase inhibitors using a conjoint analysis	8
Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome	8
Effect of direct oral feeding following minimally invasive esophagectomy on costs and quality of life	8
Epidemiology, healthcare resource utilization and healthcare costs for spinal muscular atrophy in Alberta, Canada	8
An economic evaluation of vagus nerve stimulation as an adjunctive treatment to anti-seizure medications for the treatment of drug-resistant epilepsy in England	8
Cost-effectiveness of andexanet alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage in the US	8
Dose escalation and associated costs in biologic treatment of psoriasis based on real-world data	8
US payer budget impact of a microarray assay with machine learning to evaluate kidney transplant rejection in for-cause biopsies	8
Health care resource utilization patterns among patients with Parkinson’s disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics	8
Economic burden of subsequent fracture in osteoporosis patients in South Korea	8
Identifying disability level in multiple sclerosis patients in a U.S.-based health plan claims database	7
Cost-effectiveness of Lutetium [177Lu] oxodotreotide versus best supportive care with octreotide in patients with midgut neuroendocrine tumors in France	7
Economic and clinical burden of managing transfusion-dependent β-thalassemia in the United States	7
Phase-specific and lifetime economic burden of cervical cancer and endometrial cancer in a commercially insured United States population	7
Cost-effectiveness analysis of the Parkinson’s KinetiGraph and clinical assessment in the management of Parkinson's disease	7
Changes in mortality associated with cancer drug approvals in the United States from 2000 to 2016	7
Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants	7
Evaluating the cost-utility of a direct transfer to angiosuite protocol within 6 h of symptom onset in suspected large vessel occlusion patients	7
Hospitalization charges for extremely preterm infants: a ten-year analysis in Shanghai, China	7
Cost-effectiveness of a paclitaxel-eluting stent (Eluvia) compared to Zilver PTX for endovascular femoropopliteal intervention	7
Retrospective analysis of adherence to HIV treatment and healthcare utilization in a commercially insured population	7
Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US	7
Comprehensive value assessments for new pediatric pneumococcal conjugate vaccines	7
Dapagliflozin cost-effectiveness analysis in heart failure patients in Egypt	7
Benefits of fracture liaison services (FLS) in four Latin American countries: Brazil, Mexico, Colombia, and Argentina	7
Artificial intelligence (AI) in pharmacy: an overview of innovations	7
Incremental net monetary benefit of herpes zoster vaccination: a systematic review and meta-analysis of cost-effectiveness evidence	7
Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities	7
Burden of acromegaly in the United States: increased health services utilization, location of care, and costs of care	7
Evaluating the burden of pruritus due to atopic dermatitis in Japan by patient-reported outcomes	7
A review of the cost-effectiveness of genetic testing for germline variants in familial cancer	7
Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson’s disease patients treated with levodopa/carbidopa	7
The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States	7
A cost-utility analysis of SIR-Spheres Y-90 resin microspheres versus best supportive care in the treatment of unresectable metastatic colorectal cancer refractory to chemotherapy in the UK	7
Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year data	7
Cost-effectiveness analysis of anti–IL-5 therapies of severe eosinophilic asthma in Spain	7
A systematic review of SF-6D health state valuation studies	7
Targeted literature review of the burden of extraintestinal pathogenic Escherichia Coli among elderly patients in Asia Pacific regions	6
Real-world migraine-related healthcare resource utilization and costs associated with improved vs. worsened/stable migraine: a panel-based chart review in France, Germany, Italy, and Spain	6
Comparative efficacy, safety, and cost-effectiveness of abobotulinumtoxinA and onabotulinumtoxinA in children with upper limb spasticity: a systematic literature review, indirect treatment comparison,	6
Cost of hemophilia A in Turkey: an economic disease burden analysis	6
Estimating the preferences and willingness-to-pay for colorectal cancer screening: an opportunity to incorporate the perspective of population at risk into policy development in Thailand	6
Healthcare resource utilization and costs for hip dislocation following primary total hip arthroplasty in the medicare population	6
Modeling the optimal sequence of biologic therapies in plaque psoriasis in Spain	6
Cost-effectiveness analysis of intradiscal condoliase injection vs. surgical or conservative treatment for lumbar disc herniation	6
Healthcare resource utilization and costs of cardiovascular events in patients with atherosclerotic cardiovascular disease in Germany – results of a claims database study	6
Epidemiology, management, and economic impact of acute myeloid leukemia and myelodysplastic syndrome in Spain at the hospital level: a claims database analysis	6
Healthcare utilization and cost burden of Huntington’s disease among Medicare beneficiaries in the United States	6
Cost-effectiveness of high dose versus adjuvanted trivalent influenza vaccines in England and Wales	6
Budget impact analysis: can we afford the added value?	6
Using electronic health record data to identify comparator populations for comparative effectiveness research	6
Healthcare resource utilization and costs of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization	6
Economic evaluation of home medication review by community pharmacists (HMR-CP) for patients with type 2 diabetes mellitus (T2DM)	6
Payer budget impact of an artificial intelligence in vitro diagnostic to modify diabetic kidney disease progression	6
Biosimilar pegfilgrastim may offer affordable treatment options for patients in France: a budget impact analysis on the basis of clinical trial and real-world data	5
Reply to the concerns raised by McKenna and Heaney about COSMIN	5
Gaps in digital health policies: an insight into the current landscape	5
Cost-effectiveness of a novel, non-active implantable device as a treatment for refractory gastro-esophageal reflux disease	5
Oncology drugs and added benefit: insights from 3 European health technology assessment agencies on the role of efficacy endpoints	5
Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantati	5
Two-year PAD-related health care costs in patients undergoing lower extremity endovascular revascularization: results from the LIBERTY 360° trial	5
Continuing trends in U.S. brand-name and generic drug competition	5
Healthcare utilization and expenditures associated with hyperkalemia management: a retrospective study of Medicare Advantage patients	5

A systematic review evaluating the efficacy and factor consumption of long-acting recombinant factor VIII products for the prophylactic treatment of hemophilia A	5
Healthcare resource utilization and exacerbations in patients with chronic obstructive pulmonary disease treated with nebulized glycopyrrolate in the USA: a real-world data analysis	5
Cost-effectiveness of pembrolizumab + chemotherapy versus chemotherapy and pembrolizumab monotherapy in first line treatment of NSCLC in the US – updated analyses with additional trial follow-up	5
Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors	5
Continuity and change in the drug supply chain: actors, actions, and aversions	5
Cost, healthcare utilization, and outcomes of antibody-mediated rejection in kidney transplant recipients in the US	5
Clinical and economic evaluation of a proteomic biomarker preterm birth risk predictor: cost-effectiveness modeling of prenatal interventions applied to predicted higher-risk pregnancies within a larg	5
Early health economic modelling for a treatment candidate in hidradenitis suppurativa	5
Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China	5
Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose	5
Comparison of utilization and cost of healthcare services and pharmacotherapy following implantation of vagus nerve stimulation vs. responsive neurostimulation or deep b	5
Cost-effectiveness analysis of double low-dose budesonide and low-dose budesonide plus montelukast among pediatric patients with persistent asthma receiving Step 3 treatment in China	5
The role of machine learning in healthcare responses to pandemics: maximizing benefits and filling gaps	5
Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK	5
A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer	5
Willingness to pay for primary health care at public facilities in the Western Cape Province, Cape Town, South Africa	5
Cost-effectiveness of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis	5
Cost-effectiveness analysis of defibrotide in the treatment of patients with severe veno-occlusive disease/sinusoidal obstructive syndrome with multiorgan dysfunction following hematopoietic cell tran	5
A breath of fresh AIR: reducing the carbon footprint of asthma	5
Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian pri	5
Economic evaluation of a vision-based patient monitoring and management system in addition to standard care for adults admitted to psychiatric intensive care units in England	5
Real-world data analysis of the clinical and economic burden and risk factors in patients with major depressive disorder with an inadequate response to initial antidepressants	5
The incidence and economic burden of extrapyramidal symptoms in patients with schizophrenia treated with second generation antipsychotics in a Medicaid population	5
The improved survival rate and cost-effectiveness of a 7-day continuous subcutaneous insulin infusion set	5
Heterogeneity of the long-term economic burden of severe sickle cell disease: a 5-year longitudinal analysis	5
Economic evaluation of polatuzumab-bendamustine-rituximab vs. tafasitamab-lenalidomide in transplant-ineligible R/R DLBCL	5
Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases	5
Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan	5
Health state utilities associated with weight loss in type 2 diabetes and obesity	5
Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis	5
A discrete-choice experiment to elicit the treatment preferences of patients with hidradenitis suppurativa in the United States	4
Estimating hospital inpatient cost-savings with sucroferric oxyhydroxide in patients on chronic hemodialysis in five European countries: a cost analysis	4
Global burden and economic impact of vaccine-preventable cancer mortality	4
Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France	4
Cost-effectiveness analysis of arthroscopic injection of a bioadhesive hydrogel implant in conjunction with microfracture for the treatment of focal chondral defects of the knee – an Australian perspe	4
Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity in a US population	4
Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States	4
Evaluation of access to care issues in patients with breast cancer	4
How accurate are the longer-term projections of overall survival for cancer immunotherapy for standard versus more flexible parametric extrapolation methods?	4
Real-world retrospective analysis of patient characteristics, healthcare resource utilization, costs, and treatment patterns among unvaccinated adults with COVID-19 diagnosed in outpatient settings in	4
Reflex single-gene non-invasive prenatal testing is associated with markedly better detection of fetuses affected with single-gene recessive disorders at lower cost	4
Does meta-analysis of economic evaluations have the potential to play a role in healthcare decision-making in the United States?	4
The cost-effectiveness of abobotulinumtoxinA (Dysport) and onabotulinumtoxinA (Botox) for managing spasticity of the upper and lower limbs, and cervical dystonia	4
Limitations of standard cost-effectiveness methods for health technology assessment of treatments for rare, chronic diseases: a case study of treatment for cystic fibrosis	4
Public health impact of booster vaccination against COVID-19 in the UK during Delta variant dominance in autumn 2021	4
Antipsychotic utilization, healthcare resource use and costs, and quality of care among fee-for-service Medicare beneficiaries with schizophrenia in the United States	4
Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia	4
Healthcare resource utilization and costs of care in the United States for patients with non-alcoholic steatohepatitis	4
Is there a correlation between total fertility rate, utilization of assisted reproduction technology, and national wealth in Europe?	4
Economic evaluation using dynamic transition modeling of ebola virus vaccination in lower-and-middle-income countries	4
Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital	4
The implications of suboptimal year-1 outcomes with disease-modifying therapy in employees with multiple sclerosis	4
Improved hospital discharge and cost savings with esophageal cooling during left atrial ablation	4
Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on esketamine intranasal spray and covered by US commercial health plans	4
How AI is advancing asthma management? Insights into economic and clinical aspects	4
A budget impact analysis of gilteritinib for the treatment of relapsed or refractoryFLT3mut+acute myeloid leukemia in a US health plan	4
Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials	4
Cost-effectiveness and cost-utility analysis of somatrogon once-weekly injections vs. daily growth hormone injection for treating paediatric growth hormone deficiency in Ireland	4
Budget impact analysis of transcatheter aortic valve replacement in low, intermediate, and high-risk patients with severe aortic stenosis in Saudi Arabia	4
Why are digital health policies crucial?	4
Cost analysis of the impact of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura from a US hospital perspective	4
Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring METex14 skipping alterations in the United States	4
A cost-effectiveness analysis of patiromer for the treatment of hyperkalemia in chronic kidney disease patients with and without heart failure in Spain	4
Cost-effectiveness of brentuximab vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in China	4
Economic evaluation of a vision-based patient monitoring and management system in an acute adult and an older adult mental health hospital in England	4
Beyond medicines’ barriers: exploring the true cost of multiple myeloma	4
Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) in the United States	4
Utilization of anticoagulants and predictors of treatment among hospitalized patients with atrial fibrillation in the USA	4
Ten-year cost-consequence analysis of weight loss on obesity-related outcomes in privately insured adults with obesity in Saudi Arabia	4
An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy	4
Systematic literature review of health economic models developed for multiple myeloma to support future analyses	4
The healthcare resource utilization and costs of chronic lung allograft dysfunction following lung transplantation in patients with commercial insurance in the United States	4
COSMIN reviews: the need to consider measurement theory, modern measurement and a prospective rather than retrospective approach to evaluating patient-based measures	4
Antiviral use is associated with a decrease in the rate of influenza-related complications, health care resource utilization, and costs	4
Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Sa	3
Impact of reimbursement restriction on drug market sales under the National Health Insurance in Japan	3
Hospital care and medical costs of septic arthritis in Spain: a retrospective multicenter analysis	3
Costs of biomarker testing among patients with metastatic lung or thyroid cancer in the USA: a real-world commercial claims database study	3
An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States	3
Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data	3
A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service	3
The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive ind	3
Influence of neurovascular embolic coil primary wind diameter on aneurysm packing density and case costs	3
Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysis	3
Frequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States	3
Cost-effectiveness of fingolimod versus interferon-β1a for the treatment of pediatric-onset multiple sclerosis in Canada	3
Clinical and economic impact of ferric carboxymaltose treatment for iron deficiency in patients stabilized following acute heart failure: a multinational study	3
Identification and temporal trends of patients with neuromyelitis optica spectrum disorder in a US insurance claims database	3
Healthcare resource utilization and costs in individuals with Huntington’s disease by disease stage in a US population	3
A device category economic model of electrosurgery technologies across procedure types: a U.S. hospital budget impact analysis	3
Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland	3
Advancing towards a worldwide healthcare system in the post-COVID-19 era: benefits and barriers to international collaboration in healthcare	3
Patients treated with pimavanserin or quetiapine for Parkinson’s disease psychosis: analysis of health resource utilization patterns among Medicare beneficiaries	3
Healthcare resource utilization, costs and treatment patterns in patients with bipolar disorder treated with lurasidone or cariprazine	3
Economic evaluation of supplemental breast cancer screening modalities to mammography or digital breast tomosynthesis in women with heterogeneously and extremely dense breasts and average or intermedi	3